Fueling Innovation: Poseida Therapeutics Secures $1.5B as Mirati Integrates into Bristol Myers Squibb to Target Cancer’s Genetic Drivers

In a transformative milestone for the biotech industry, Poseida Therapeutics is proud to announce a successful funding round that has raised an impressive $1.5 billion. This extraordinary infusion of capital not only reflects the unwavering confidence of investors but also signals a new era of innovation in the development of advanced therapies. As Poseida Therapeutics continues to push the boundaries of precision medicine, these funds will be strategically allocated to accelerate critical research and development programs, optimize clinical trial processes, and expand our state-of-the-art manufacturing capabilities. Our goal is to expedite the delivery of next-generation treatments that target the underlying genetic drivers of cancer—a mission that resonates deeply within the scientific community and offers renewed hope for patients worldwide. In drawing inspiration from industry trailblazers, it is noteworthy that Mirati Therapeutics, Inc.—now part of the esteemed Bristol Myers Squibb family—has laid a robust foundation in the realm of breakthrough oncology therapies. Their pioneering advancements in targeting cancer’s genetic anomalies have set a high benchmark, and we are both honored and motivated to advance our own pipeline in a similar spirit of innovation and excellence. With this significant funding milestone, Poseida Therapeutics is uniquely positioned to drive forward transformative research that could redefine cancer treatment paradigms. We invite you to join us on this remarkable journey as we work tirelessly to develop therapies that offer lasting impact and to keep abreast of all our progress. Follow our progress as we deliver breakthrough therapies by connecting with Bristol Myers Squibb or visiting www.bms.com for further insights and updates.